De novo hepatocellular carcinoma of liver allograft: A neglected issue

Cancer Letters

Volumn 357, Issue 1, 2015, Pages 47-54

  Trevisani, Franco ^a   Garuti, Francesca ^a   Cucchetti, Alessandro ^a   Lenzi, Barbara ^a   Bernardi, Mauro ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

De novo carcinogenesis; Liver transplantation; Recurrence; Risk factors

Indexed keywords

AFLATOXIN B1; ANTIVIRUS AGENT; AROMATIC AMINE; ARSENIC; AZATHIOPRINE; AZO DYE; BASILIXIMAB; CORTICOSTEROID; CYCLOSPORIN; EVEROLIMUS; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NITROSAMINE; NUCLEOSIDE ANALOG; OKT 3; ORGANIC SOLVENT; PESTICIDE; PREDNISONE; RAPAMYCIN; RIBAVIRIN; SOFOSBUVIR; TACROLIMUS; VINYL CHLORIDE;

ANTINEOPLASTIC ACTIVITY; CANCER INCIDENCE; CANCER PREVENTION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CHEMOEMBOLIZATION; CHEMOPROPHYLAXIS; CLINICAL FEATURE; DE NOVO LIVER CELL CARCINOMA; DIAGNOSTIC IMAGING; DRUG MEGADOSE; FLUORESCENCE IN SITU HYBRIDIZATION; GRAFT INFECTION; GRAFT RECIPIENT; HEPATITIS B; HEPATITIS C; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER GRAFT; LIVER RESECTION; LIVER TRANSPLANTATION; LUNG METASTASIS; NONHUMAN; POLYMERASE CHAIN REACTION; RADIOFREQUENCY ABLATION; RECURRENCE RISK; RETRANSPLANTATION; RISK FACTOR; SHORT SURVEY; SMOKING; ADVERSE EFFECTS; AGED; ALLOGRAFT; CARCINOMA, HEPATOCELLULAR; FEMALE; LIVER NEOPLASMS; MALE; MIDDLE AGED; PATHOLOGY; PROCEDURES; TUMOR RECURRENCE;

AGED; ALLOGRAFTS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RISK FACTORS;

EID: 84920489105     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.11.032     Document Type: Review

References (63)

1. Ferlay J., Soerjomataram I., Ervik M., et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet] Lyon, France: International Agency for Research on Cancer accessed 23.04.14. http://globocan.iarc.fr.
2. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol 2012, 56:908-943.
3. Bruix J., Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011, 53:1020-1022. American Association for the Study of Liver Diseases.
4. Poon D., Anderson B.O., Chen L.T., et al. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 2009, 10:1111-1118.
5. Mazzaferro V., Regalia E., Doci R., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Engl. J. Med 1996, 334:693-699.
6. Zimmerman M.A., Ghobrial R.M., Tong M.J., et al. Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators. Arch. Surg 2008, 143:182-188. discussion 188.
7. Michel J., Suc B., Montpeyroux F., et al. Liver resection or transplantation for hepatocellular carcinoma? Retrospective analysis of 215 patients with cirrhosis. J. Hepatol 1997, 26:1274-1280.
8. Ringe B., Wittekind C., Bechstein W.O., et al. The role of liver transplantation in hepatobiliary malignancy. A retrospective analysis of 95 patients with particular regard to tumor stage and recurrence. Ann. Surg 1989, 209:88-98.
9. O'Grady J.G., Polson R.J., Rolles K., et al. Liver transplantation for malignant disease. Results in 93 consecutive patients. Ann. Surg 1988, 207:373-379.
10. Yokoyama I., Todo S., Iwatsuki S., et al. Liver transplantation in the treatment of primary liver cancer. Hepatogastroenterology 1990, 37:188-193.
11. Chak E., Saab S. Risk factors and incidence of de novo malignancy in liver transplant recipients: a systematic review. Liver Int 2010, 30:1247-1258.
12. Al-Joundi T., Gibson S., Brunt E.M., et al. Delayed recurrence of hepatocellular carcinoma after liver transplantation: detection of origin by chromosomal analysis. Liver Transpl 2000, 6:374-375.
13. Hoffmann C.J., Subramanian A.K., Cameron A.M., et al. Incidence and risk factors for hepatocellular carcinoma after solid organ transplantation. Transplantation 2008, 86:784-790.
14. Adam R., Karam V., Delvart V., et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J. Hepatol 2012, 57:675-688.
15. Angelico M., Cillo U., Fagiuoli S., et al. Liver Match, a prospective observational cohort study on liver transplantation in Italy: study design and current practice of donor-recipient matching. Dig. Liver Dis 2011, 43:155-164.
16. Strautnieks S., Thompson R.J., Amarapurkar A., et al. De novo hepatocellular carcinoma in allograft liver with background of hepatitis C virus infection, cirrhosis and previous genetically distinct HCC in native liver [AASDL abstract 1874]. Hepatology 2001, 4. 640 A.
17. Morita K., Taketomi A., Soejima Y., et al. De novo hepatocellular carcinoma in a liver graft with sustained hepatitis C virus clearance after living donor liver transplantation. Liver Transpl 2009, 15:1412-1416.
18. Saxena R., Ye M.Q., Emre S., et al. De novo hepatocellular carcinoma in a hepatic allograft with recurrent hepatitis C cirrhosis. Liver Transpl. Surg 1999, 5:81-82.
19. Levitsky J., Faust T.W., Cohen S.M., et al. Group G streptococcal bacteremia and de novo hepatocellular carcinoma after liver transplantation. Liver Transpl 2002, 8:572.
20. Flemming P., Tillmann H.L., Barg-Hock H., et al. Donor origin of de novo hepatocellular carcinoma in hepatic allografts. Transplantation 2003, 76:1625-1627.
21. Torbenson M., Grover D., Boitnott J., et al. De novo hepatocellular carcinoma in a liver allograft associated with recurrent hepatitis B. Transplant. Proc 2005, 37:2205-2206.
22. Croitoru A., Schiano T.D., Schwartz M., et al. De novo hepatocellular carcinoma occurring in a transplanted liver: case report and review of the literature. Dig. Dis. Sci 2006, 51:1780-1782.
23. Sotiropoulos G.C., Frilling A., Molmenti E.P., et al. De novo hepatocellular carcinoma in recurrent liver cirrhosis after liver transplantation for benign hepatic disease: is a deceased donor re-transplantation justified?. Transplantation 2006, 82:1112.
24. Kita Y., Klintmalm G., Kobayashi S., et al. Retransplantation for de novo hepatocellular carcinoma in a liver allograft with recurrent hepatitis B cirrhosis 14 years after primary liver transplantation. Dig. Dis. Sci 2007, 52:3392-3393.
25. Vernadakis S., Poetsch M., Weber F., et al. Donor origin de novo HCC in a noncirrhotic liver allograft 3 years after liver transplantation. Transpl. Int 2010, 23:341-343.
26. Yu S., Guo H., Zhuang L., et al. A case report of de novo hepatocellular carcinoma after living donor liver transplantation. World J. Surg. Oncol 2013, 11:176.
27. Yu S., Gao F., Yu J., et al. De novo cancers following liver transplantation: a single center experience in China. PLoS ONE 2014, 9. e85651.
28. Finkelstein S.D., Marsh W., Demetris A.J., et al. Microdissection-based allelotyping discriminates de novo tumor from intrahepatic spread in hepatocellular carcinoma. Hepatology 2003, 37:871-879.
29. Altimari A., Gruppioni E., Fiorentino M., et al. Genomic allelotyping for distinction of recurrent and de novo hepatocellular carcinoma after orthotopic liver transplantation. Diagn. Mol. Pathol 2005, 14:34-38.
30. Vivarelli M., Bellusci R., Cucchetti A., et al. Low recurrence rate of hepatocellular carcinoma after liver transplantation: better patient selection or lower immunosuppression?. Transplantation 2002, 74:1746-1751.
31. Vivarelli M., Cucchetti A., La Barba G., et al. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence. Ann. Surg 2008, 248:857-862.
32. Øzbay L.A., Smidt K., Mortensen D.M., et al. Cyclosporin and tacrolimus impair insulin secretion and transcriptional regulation in INS-1E beta-cells. Br. J. Pharmacol 2011, 162:136-146.
33. Soleimanpour S.A., Crutchlow M.F., Ferrari A.M., et al. Calcineurin signaling regulates human islet {beta}-cell survival. J. Biol. Chem 2010, 285:40050-40059.
34. Chakkera H.A., Mandarino L.J. Calcineurin inhibition and new-onset diabetes mellitus after transplantation. Transplantation 2013, 95:647-652.
35. El-Serag H.B., Hampel H., Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin. Gastroenterol. Hepatol 2006, 4:369-380.
36. Rodríguez-Perálvarez M., Tsochatzis E., Naveas M.C., et al. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. J. Hepatol 2013, 59:1193-1199.
37. Rodríguez-Perálvarez M., De la Mata M., Burroughs A.K. Liver transplantation: immunosuppression and oncology. Curr. Opin. Organ. Transplant 2014, 19:253-260.
38. Villanueva A., Chiang D.Y., Newell P., et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008, 135:1972-1983. 1983.e1-11.
39. Gaumann A., Schlitt H.J., Geissler E.K. Immunosuppression and tumor development in organ transplant recipients: the emerging dualistic role of rapamycin. Transpl. Int 2008, 21:207-217.
40. Piguet A.C., Semela D., Keogh A., et al. Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma. J. Hepatol 2008, 49:78-87.
41. Schnitzbauer A.A., Zuelke C., Graeb C., et al. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer 2010, 10:190.
42. Tong M.J., el-Farra N.S., Reikes A.R., et al. Clinical outcomes after transfusion-associated hepatitis C. N. Engl. J. Med 1995, 332:1463-1466.
43. Iwatsuki S., Starzl T.E., Sheahan D.G., et al. Hepatic resection versus transplantation for hepatocellular carcinoma. Ann. Surg 1991, 214:221-228. discussion 228-9.
44. Shetty K., Timmins K., Brensinger C., et al. Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl 2004, 10:911-918.
45. Löhe F., Angele M.K., Gerbes A.L., et al. Tumour size is an important predictor for the outcome after liver transplantation for hepatocellular carcinoma. Eur. J. Surg. Oncol 2005, 31:994-999.
46. Jonas S., Bechstein W.O., Steinmüller T., et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001, 33:1080-1086.
47. Todo S., Furukawa H. Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Ann. Surg 2004, 240:451-459. Japanese Study Group on Organ Transplantation, discussion 459-61.
48. Bismuth H., Chiche L., Adam R., et al. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann. Surg 1993, 218:145-151.
49. Samoylova M.L., Dodge J.L., Vittinghoff E., Yao F.Y., Roberts J.P. Validating posttransplant hepatocellular carcinoma recurrence data in the United Network for Organ Sharing database. Liver Transpl 2013, 19:1318-1323.
50. Nagai S., Yoshida A., Facciuto M., Moonka D., Abouljoud M.S., Schwartz M.E., et al. Ischemia time impacts recurrence of hepatocellular carcinoma following liver transplantation. Hepatology 2014, Epub ahead of print. 10.1002/hep.27358.
51. Mazzaferro V., Llovet J.M., Miceli R., et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009, 10:35-43.
52. Roayaie S., Schwartz J.D., Sung M.W., et al. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl 2004, 10:534-540.
53. Schlitt H.J., Neipp M., Weimann A., et al. Recurrence patterns of hepatocellular and fibrolamellar carcinoma after liver transplantation. J. Clin. Oncol 1999, 17:324-331.
54. Roh Y.N., David Kwon C.H., Song S., et al. The prognosis and treatment outcomes of patients with recurrent hepatocellular carcinoma after liver transplantation. Clin. Transplant 2014, 28:141-148.
55. Chan K.M., Chou H.S., Wu T.J., et al. Characterization of hepatocellular carcinoma recurrence after liver transplantation: perioperative prognostic factors, patterns, and outcome. Asian J. Surg 2011, 34:128-134.
56. Chok K.S., Chan S.C., Cheung T.T., et al. Late recurrence of hepatocellular carcinoma after liver transplantation. World J. Surg 2011, 35:2058-2062.
57. Castroagudín J.F., Molina-Pérez E., Ferreiro-Iglesias R., Abdulkader I., Otero-Antón E., Tomé S., et al. Late recurrence of hepatocellular carcinoma after liver transplantation: is an active surveillance for recurrence needed?. Transplant. Proc 2012, 44:1565-1567.
58. Xiao S.Y., Lu L., Wang H.L. Fibrosing cholestatic hepatitis: clinicopathologic spectrum, diagnosis and pathogenesis. Int. J. Clin. Exp. Pathol 2008, 1:396-402.
59. Farazi P.A., DePinho R.A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer 2006, 6:674-687.
60. Kleeberger W., Rothämel T., Glöckner S., et al. High frequency of epithelial chimerism in liver transplants demonstrated by microdissection and STR-analysis. Hepatology 2002, 35:110-116.
61. Bolondi L., Cillo U., Colombo M., et al. Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma. Dig. Liver Dis 2013, 45:712-723. Italian Association for the Study of the Liver (AISF), AISF Expert PanelAISF Expert Panel, AISF Coordinating CommitteeAISF Coordinating Committee.
62. Curry M., Forns X., Chung R., et al. Pretransplant sofosbuvir and ribavirin to prevent recurrence of HCV infection after liver transplantation. Hepatology 2013, 58. 314A.
63. Faure S., Herrero A., Jung B., et al. Excessive alcohol consumption after liver transplantation impacts on long-term survival, whatever the primary indication. J. Hepatol 2012, 57:306-312.